Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
About
About
EQOH
Careers
Contact Us
EMJ Gold
search
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
About
About
EQOH
Careers
Contact Us
EMJ Gold
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
14th October 2015
ECC 2015: News briefing chaired by Prof Martine Piccart
At the European Cancer Congress (ECC) 2015, Martine Piccart, MD, PhD, of Université Libre de Bruxelles and Institut Jules Bordet, Brussels, Belgium…
14th October 2015
ECC 2015: CheckMate 025 trial showed nivolumab improved overall survival in advanced kidney cancer
CheckMate 025, a phase 3 clinical trial, compared the anti-programmed cell death protein-1 (PD-1) antibody, nivolumab, with the standard treatment…
14th October 2015
ECC 2015: EUROCARE-5 trial showed large variations in blood cancer survival in Europe
Comparisons of cancer patients’ survival and care in Europe up to 2007 showed that although more patients are surviving for at least five years after…
14th October 2015
ECC 2015: METEOR trial showed cabozantinib improved survival in advanced kidney cancer
METEOR, a phase 3 clinical trial, compared cabozantinib with everolimus for the treatment of patients with advanced clear cell renal cell carcinoma.
14th October 2015
The value of an intermediate Recurrence Score® result in the Oncotype DX® Breast Cancer Assay
The Oncotype DX® Breast Cancer Assay is a 21-gene assay that provides a Recurrence Score® (RS), which is divided into low-, intermediate- and high-risk…
14th October 2015
TERRAIN trial of enzalutamide versus bicalutamide for advanced prostate cancer
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC…
14th October 2015
Assessing the eligibility of a breast cancer patient for genomic testing
Genomic tests, such as the Oncotype DX® Breast Cancer Assay, provide results that quantify recurrence risk and identify patients who are likely or…
14th October 2015
Updated results of a phase 1a study of anti-PDL1, MPDL3280A, in urothelial bladder cancer
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Thomas Powles, MBBS, MRCP, MD, of Barts Cancer Institute, Queen Mary University…
14th October 2015
Experience of the Oncotype DX® Breast Cancer Assay in the clinic
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Harold J. Burstein, MD, PhD, of Dana-Farber Cancer Institute, Boston, MA…
4
Mins
12th October 2015
European Liver Patients’ Association (ELPA) Launches Call to Action Report for the Treatment of Hepatic Encephalopathy
BRUSSELS, BELGIUM, 12 October 2015, 18:30 CET – ELPA today launched a new call to action report ‘Time to DeLiver: Getting a Grip on HE’ at the…
←
1
2
3
…
813
814
815
816
817
818
819
…
897
898
899
→